This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days - WEBINAR

Share this article

In three weeks, AbCellera discovered and characterized hundreds of unique antibodies against SARS-CoV-2 from one of the first U.S. patients to recover from COVID-19. AbCellera's full-stack AI-powered antibody discovery platform searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

AbCellera’s team analyzed hundreds of thousands of corresponding characterization and neutralization data points using bioinformatic analysis to identify therapeutic lead candidates, including bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. FDA.

Presented by Kevin Heyries, Co-founder at AbCellera, this webinar is an Antibody Technology Spotlight Session and part of the Antibody Engineering & Therapeutics Asia Virtual Scientific Forum which took place on 5-7 April, 2021.

Share this article

Upcoming event

Antibody Engineering & Therapeutics US

12 - 16 Dec 2021, Marriott Marquis San Diego
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS
Go to site